CellSource Co., Ltd.
CellSource Co., Ltd. fiscal year ending October 2026 Q3 financial results briefing materials
Revenue declined year over year, including a revision of the full-year outlook. Indicates segment contributions and improvements in cost structure. Contributions from AI-related and exosome-related businesses and others varied versus the previous period.
Key Figures
- Net sales: 2,557 million yen (YoY -9.2%)
- Operating income: 179 million yen (YoY +45.3%)
- Gross profit margin: 58.9%–59.6% (approximately +1.3pt)
AI要約
業績の概要
For the third quarter of the fiscal year ending October 2026, revenue was flat to slightly down versus the previous period, while operating income improved significantly. Key drivers are cost control and productivity improvements. Contributions from certain segments, such as self-funded orthopedic care and exosome-related businesses, varied versus the prior period. The company’s overall revenue mix remains diversified, with cosmetics sales appearing as a headwind.
今後の見通しと資本政策
The outlook includes potential revisions to full-year earnings; explanations of key measures and progress, particularly in contract processing services, medical device sales, and PAJUU, outlining growth strategies. Ongoing progress in new businesses and cost-reduction efforts are expected to support profit improvement in the next period.
CellSource Co., Ltd.
Company overview · Stock price · Financial data · All IR
